LADENBURG THALM/SH SH Raises Marker Therapeutics (NASDAQ:MRKR) Price Target to $19.00

Marker Therapeutics (NASDAQ:MRKR) had its price objective boosted by LADENBURG THALM/SH SH from $11.00 to $19.00 in a report released on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

Marker Therapeutics Trading Down 0.7 %

MRKR stock opened at $4.51 on Monday. Marker Therapeutics has a 12 month low of $2.40 and a 12 month high of $6.16. The company’s 50 day simple moving average is $3.11 and its 200-day simple moving average is $3.97.

Marker Therapeutics (NASDAQ:MRKR) last announced its earnings results on Wednesday, August 14th. The company reported ($0.25) EPS for the quarter. Marker Therapeutics had a negative net margin of 278.27% and a negative return on equity of 78.91%. The company had revenue of $1.17 million for the quarter. As a group, analysts predict that Marker Therapeutics will post -1.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Marker Therapeutics stock. Wedbush Securities Inc. lifted its position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 69,500 shares of the company’s stock after buying an additional 24,000 shares during the period. Wedbush Securities Inc. owned 0.78% of Marker Therapeutics worth $377,000 as of its most recent SEC filing. 22.39% of the stock is owned by institutional investors and hedge funds.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.